Lonza Group AG

The refocused CDMO strategy is already delivering results, as evidenced by the landmark multi-billion CHF biologics partnership expansion, which validates Lonza's repositioning as a high-value biologics and advanced therapies manufacturer and strengthens its long-term commercial pipeline.

Divesting the Capsules & Health Ingredients business strips away a diversified, stable revenue stream, leaving Lonza more exposed to the volatility and concentration risks inherent in pure-play CDMO operations, where a single facility issue or FDA warning letter could significantly disrupt manufacturing and revenues.

The global biologics manufacturing market is projected to more than double from USD 41.2 billion in 2025 to USD 89.7 billion by 2035 at an 8.08% CAGR, and Lonza's Swiss facility expansion and deepening client partnerships position it to capture a substantial share of this structural growth.

Lonza's heavy capital commitment to expanding biologics manufacturing capacity carries significant execution risk. The company's reliance on a concentrated set of large multi-program partnerships means any client attrition, clinical failure in partner pipelines, or manufacturing disruption could undermine the returns on these investments.

Lonza's sticky long-term contracts, high customer switching costs in its pharma and biotech segments, and a supportive Swiss and global equity environment — with the Swiss Market Index recently hitting 52-week highs — provide a solid fundamental and macro backdrop for sustaining elevated valuations.

Lonza's stock is currently trading at a 422% premium to Morningstar's fair value estimate of CHF 795.00, with a 1-star price threshold at CHF 765.70, suggesting the market has significantly overpriced the stock relative to its intrinsic value, leaving limited upside and meaningful downside risk for investors.